Cargando…
Ovarian Cancer Targeted Theranostics
Ovarian cancer is a leading cause of death from gynecological malignancies. Although the prognosis is quite favorable if detected at an early stage, the vast majority of cases are diagnosed at an advanced stage, when 5-year survival rates are only 30–40%. Most recurrent ovarian tumors are resistant...
Autores principales: | Nimmagadda, Sridhar, Penet, Marie-France |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985364/ https://www.ncbi.nlm.nih.gov/pubmed/32039018 http://dx.doi.org/10.3389/fonc.2019.01537 |
Ejemplares similares
-
PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation
por: Pacheco-Torres, Jesus, et al.
Publicado: (2021) -
Ascites Volumes and the Ovarian Cancer Microenvironment
por: Penet, Marie-France, et al.
Publicado: (2018) -
Differential Expression of Chemokine Receptors and their Roles in Cancer Imaging
por: Nimmagadda, Sridhar
Publicado: (2012) -
PD-L1 near Infrared Photoimmunotherapy of Ovarian Cancer Model
por: Jin, Jiefu, et al.
Publicado: (2022) -
Effect of Pantethine on Ovarian Tumor Progression and Choline Metabolism
por: Penet, Marie-France, et al.
Publicado: (2016)